FDA perspective | Kellie Reynolds, PharmD

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017

HBV therapy & Approaches to Cure | Jordan Feld, MD, MPH

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017

Clinical Aspects of Pediatric Treatment | Tim Cressey, PhD

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017

Current Challenges in Pediatric Drug Development | Robert Ward, MD, FAAP, FCP

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017

Current and Future Treatment of CMV | Robin Avery, MD

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017

Management of DAA Failures | Gregory T. Everson, MD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

Post-LT Renal Failure and HCV Rx | Peter Ferenci, MD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

Obstacles to Treatment: Renal Disease, Ribavirin, DDIs | Michael Charlton, MD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

What Are the Treatment Options? | Maria Londoño, MD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

Use of HCV+ Donor Grafts | Didier Samuel, MD, PhD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

Achieving SVR in CTP C – MELD Purgatory | Christophe Duvoux, MD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

When to Treat HCV in a Waiting List Patient? | Stefano Fagiuoli, MD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

What Are the Treatment Options? | Xavier Forns, MD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

Treatment Experienced GT3 patient with Cirrhosis | Geoffrey McCaughan, MD, PhD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

Is Treatment Cost-effective? | Kosh Agarwal, MD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

Who Should We Treat? What is the “Point-of-No-Return”? | Norah Terrault, MD, MPH, FAASLD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

Effect of antiviral therapy on liver fibrosis in patients with CHC | Dr. JiDong Jia

Asian Conference on Hepatitis and AIDS (ACHA) 2016

Is HCV drug resistance an issue? | Jürgen Rockstroh, MD

Asian Conference on Hepatitis and AIDS (ACHA) 2016

Treatment of Hepatitis C: an Asian-Pacific perspective | Dr. Sang Hoon Ahn

Asian Conference on Hepatitis and AIDS (ACHA) 2016

RNAi therapeutics for chronic HBV - Clinical data | Dr. Man-Fung Yuen

Asian Conference on Hepatitis and AIDS (ACHA) 2016

RNAi therapeutics for chronic HBV - Animal models | Dr. Bruce D. Given

Asian Conference on Hepatitis and AIDS (ACHA) 2016

New Treatments/Targets in HBV | Stephen Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)

Asian Conference on Hepatitis and AIDS (ACHA) 2016

Hepatitis B immunological pathogenesis and immunological assessment | Dr. Chao Wu

Asian Conference on Hepatitis and AIDS (ACHA) 2016

Eradication of HIV | Bonaventura Clotet, MD, PhD

Asian Conference on Hepatitis and AIDS (ACHA) 2016